Cipla Extends Losses After USFDA Inspection

shares declined 1.36% on Wednesday, August 26, extending losses for the second consecutive session. The weakness follows a USFDA follow-up current Good Manufacturing Practices (cGMP) inspection at the company’s Pithampur manufacturing facility, conducted from August 17 to 25, 2026. Following the inspection, the company received seven inspectional observations in Form 483. While Form 483 observations do not represent a final regulatory conclusion, the development remains an important near-term monitor for investors given the significance of USFDA compliance for Cipla’s manufacturing operations and US business. From a stock-price perspective, Cipla’s recent trend has remained weak. The stock has been in the red for three consecutive weeks on a weekly closing basis. If the stock remains negative through the current week, it would mark a fourth consecutive weekly decline. Today’s 1.36% fall therefore adds to the ongoing cautious sentiment around the counter, with investors likely to track further regulatory developments and management commentary closely. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes only. Investors must verify information before investing and consider their financial position & risk profile.